eISSN: 1509-572x
ISSN: 1641-4640
Folia Neuropathologica
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
4/2014
vol. 52
 
Share:
Share:
more
 
 

Original article
On the lack of a clear-cut association between alpha-2-macroglobulin deletion and the risk of Alzheimer disease in Poland

Grażyna Michałowska-Wender
,
Alicja Wawrzynek
,
Grzegorz Rossa
,
Wojciech Kozubski
,
Mieczysław Wender

Folia Neuropathol 2014; 52 (4): 417-420
Online publish date: 2014/12/30
Article file
- On the lack.pdf  [0.09 MB]
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Introduction

Alzheimer disease (AD) is a complex multi-factorial disease with the potential involvement of several genes. Alpha-2-macroglobulin (A2M) has been implicated in AD on the basis of its ability to mediate the clearance and degradation of -amyloid peptide. Nevertheless, it is not clear whether there are racial differences in frequency of polymorphisms of A2M in AD.
Association of A2M deletion polymorphism with sporadic AD was reported in Korea [11] and in southern Italy [23]. Genetic association of A2M with AD was also noted in the Finnish elderly population [16]. Similar results were reported in the USA [5,7,13]. These data seem to support the view about susceptibility for AD, linked to A2M polymorphism.
However, there are also many studies with negative results, including in Poland [21], Hungary [10], Japan [9], China [20], USA [22], Italy [17], Germany [3], France [8] and Sweden [6].
The discussed differences between various human populations may be explained by the known gene expression variability between different human populations, with the impact on disease susceptibility [14], and by biochemical individuality probably with potential relevance to AD [15].
The above, briefly presented differences regarding whether existing data point to an association between A2M polymorphism and AD justify our interest in this problem.

Material and methods

We examined a group of 50 unrelated patients from Poland (38 women and 12 men), who were diagnosed clinically as probably developing AD (according to the N1NCD3 – ADR PA criteria), including 35 patients with an onset of over 65 years of age (late AD) and 15 with an early AD (onset before the 65th year of age). The patients were examined by the neurologist and psychologist and had a CT or MRI scan of the brain. Fifty individuals of matched age, without any signs of dementia, were studied as control subjects.
DNA was extracted by a routine method from a 1 ml EDTA blood sample. All patients were pseudo-sporadic ones, without evident familiar association. Amplification and genotyping at A2M was performed as described by Blacker et al. [5].

Results

The genotype and allelic distribution were compared between controls and patients with AD. In the control group the genotype WW in A2M exon 18 was detected in 74% of individuals. Heterozygous W/ was found in 24%, and  was found in only 2% of control group individuals. Allelic distribution in the control group was 86% for W and 14% for .
The genotypic distribution in A2M exon 18 in patients with AD was similar to that in the controls. The genotype WW was detected in 32 cases (64%), while heterozygous W/ was detected in 3 cases (6%). A polymorphism (deletion) was uncovered in 4 cases. The allelic distribution was found to be 78% for W and 22% for . The comparisons of genotype and allele frequencies between the early (before 65 years) and late onset (older than 65 years) as well as between male and female patients with AD are presented in Table I. Statistically significant differences were not found.
The genotype TT in A2M exon 24 of the control group was detected in 52%, TC in 30% and CC in 18% instances. In the control group the allelic distribution was as follows: T 67% and C 33%. In AD the TT genotype in A2M exon 24 was found in 19 patients (38%), TC in 19 individuals (38%) and CC in 12 cases (29%), and the allelic distribution was C 43% and T 57%. The genotype and allele frequencies, divided according to gender, in early onset AD are presented in Table II. Significant differences were detected between the subgroup of males in early onset AD and the controls, as well as between the subgroup of females with late onset AD and the respective controls.

Discussion

The molecular basis of AD is of general interest and in recent years has been broadly discussed in very interesting review papers [1,2,18,19]. Among several genetic factors which have been implicated in AD, only a few are thought to be causative for the disease. In the majority of sporadic AD cases, genetic factors act as predisposing agents, without the capacity to induce the disease but able to increase the risk of disease above that found in the general population. They may also interact among themselves to further enhance the probability of inducing the disease (synergic effect) [21].
In our studies we have used the typical approach to evaluate the genetic contribution to the risk of AD by analyzing the frequency distribution of the allelic variants at polymorphic sites of the candidate gene, A2M, in cases of the disease and in controls. Alpha- 2-macroglobulin is a serum pan-protease inhibitor, also expressed in the brain, which has been implicated in AD on the basis of its ability to mediate the clearance and degradation of A, the major component of -amyloid deposits. Alpha-2-macroglobulin is a component of senile plaques. The A2M gene, mapped to chromosome 12p, became a candidate as a disease locus for late-onset AD. Based on the positional information about the candidate gene, Blacker et al. [5] focused on a 5 bp deletion/insertion polymorphism of the A2M gene, located in the 5’ splice site of exon 18. By using a family-based association test method, they found an association between the deletion allele (A2M-D) and late-onset AD. With a deletion, A2M may be less effective in -amyloid binding and clearance and in preventing its deposition in senile plaques. Sequencing of the RT-PCR products from the deletion and insertion homozygotes revealed no alteration in sequence from that expected, despite the loss of 5 bp adjacent to exon 18. These molecular findings suggest that A2M deletion might be nonfunctional [6].
In our studied material we have not found any clear-cut differences in the frequency of genotype and allele frequency between AD and controls. Significant differences were noted only in early onset AD in males and for old onset disease in females. The deletions were found more frequently in AD; however, they were found in only a small proportion of studied patients.
There are three biological manifestations of the A-A2M interactions that may be directly relevant to the etiology of AD [13]. First, the interaction between A2M and A prevents A fibril formation and fibril-associated neurotoxicity. Secondly, protease activation of A-A2M complexes or protease activation of A2M followed by A binding can promote the protease-mediated degradation of A2M-bound A. And thirdly, protease activated A-A2M complexes may undergo LPR-mediated endocytosis followed by trafficking of A to lysosomes for degradation. The established late-onset risk factor ApoE 4 accelerates A deposition, and ApoE is found in a complex with A2M in plasma. Taken together, these findings indicate that A2M is not the only biological candidate gene for AD determination. So far, only the ApoE 4 allele is known to be a genetic risk factor for the later onset sporadic AD.
Similar negative results in the Polish population were obtained in studies of CR1, PICALM and CLU gene polymorphisms [12]. Therefore the slightly positive results obtained in studies by Bednarska-Makaruk et al. [4] are very interesting. The authors concluded that paraoxonase 1 (PON1) gene promoter polymorphism may have a role in AD development. However, the role seems to be only an additional one.

Disclosure

Authors report no conflict of interest.

References

1. Armstrong RA. On the ‘classification’ of neurodegenerative disorders: discrete entities, overlap or continuum? Folia Neuropathol 2012; 50: 201-218.
2. Armstrong RA. What causes Alzheimer’s disease? Folia Neuropathol 2013; 51: 169-188.
3. Bagli M, Papassotiropoulos A, Jessen F, Schmitz S, Rao ML, Maier W, Heun R. Identical distribution of the alpha 2-macroglobulin pentanucleotide deletion in subjects with Alzheimer disease and controls in a German population. Am J Med Genet 2000; 96: 775-777.
4. Bednarska-Makaruk ME, Krzywkowski T, Graban A, Lipczyńska-Łojkowska W, Bochyńska A, Rodo M, Wehr H, Ryglewicz DK. Paraoxonase 1 (PON1) gene –108C>T and p.Q192R polymorphisms and arylesterase activity of the enzyme in patients with dementia. Folia Neuropathol 2013; 51: 111-119.
5. Blacker D, Wilcox MA, Laird NM, Rodes L, Horvath SM, Go RC, Perry R, Watson B Jr,Basset SS, McInnisMG, Albert MS, Hyman BT, Tanzi RE. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 1998; 19: 357-360.
6. Blennow K, Ricksten A, Prince JA, Brookes AJ, Emahazion T, Wasslavik C, Bogdanovic N, Andreasen N, Båtsman S, Marcusson J, Nägga K, Wallin A, Regland B, Olofsson H, Hesse C, Davidsson P, Minthon L, Jansson A, Palmqvist L, Rymo L. No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer’s disease, and no change in A2M mRNA, protein, or protein expression. J Neural Transm 2000; 107: 1065-1107.
7. Dodel RC, Du Y, Bales KR, Gao F, Eastwood B, Glazier B, Zimmer R, Cordell B, Hake A, Evans R, Gallagher-Thompson D, Thompson LW, Tinklenberg JR, Pfefferbaum A, Sullivan EV, Yesavage J, Alstiel L, Gasser T, Farlow MR, Murphy GM Jr, Paul SM. Alpha2 macroglobulin and the risk of Alzheimer’s disease. Neurology 2000; 54: 438-442.
8. Halimi G, Duplan L, Bideau C, Iniesta D, Berthézène P, Oddoze C, Verdier JM, Michel B, Bergé-Lefranc JL. Association of APOE promoter but not A2M polymophisms with risk of developing Alzheimer’s disease. Neuroreport 2000; 11: 3599-3601.
9. Higuchi S, Matsushita S, Nakane J, Arai H, Matsui T, Urakami K, Yuzuriha T, Takeda A. Alpha2-macroglobulin gene polymorphisms show racial diversity and are not associated with Alzheimer’s disease. Neuroreport 2000; 11: 1167-1171.
10. Janka Z, Juhász A, Rimanóczy A, Boda K, Márki-Zay J, Palotás M, Kuk I, Zöllei M, Jakab K, Kálmán J. Alpha2-macroglobulin exon 24 (Val-1000-Ile) polymorphisms is not associated with late-onset sporadic Alzheimer’s dementia in the Hungarian population. Psychiatr Genet 2002; 12: 49-54.
11. Jhoo JH, Kim KW, Lee DY, Lee KU, Lee JH, Kim SY, Youn JC, Woo JI. Association of alpha-2-macroglobulin deletion polymorphism with sporadic Alzheimer’s disease in Koreans. J Neurol Sci 2001; 184: 21-25.
12. Klimkowicz-Mrowiec A, Sado M, Dziubek A, Dziedzic T, Pera J, Szczudlik A, Slowik A. Lack of association of CR1, PICALM and CLU gene polymorphisms with Alzheimer disease in a Polish population. Neurol Neurochir Pol 2013; 47: 157-160.
13. Kovacs DM. Alpha2-macroglobulin in late-onset Alzheimer’s disease. Exp Gerontol 2000; 35: 473-479.
14. Li J, Liu Y, Kim T, Min R, Zhang Z. Gene expression variability within and between human populations and implications toward disease susceptibility. PLoS Comput Biol 2010; 6: 1-10.
15. Lukiw WJ. Variability in micro RNA (miRNA) abundance, speciation andcomplexity amongst different human populations and potential relevance toAlzheimer’s disease (AD). Front Cell Neurosci 2013; 7: 1-4.
16. Myllykangas L, Polvikoski T, Sulkava R, Verkkoniemi A, Crook R, Tienari PS, Pusa AK, Niinistö L, O`Brien P, Kontula K, Hardy J, Haltia M, Pérez-Tur J. Genetic association of alpha2-macroglobulin with Alzheimer`s disease in a Finnish elderly population. Ann Neurol 1999; 46: 382-390.
17. Nacmias B, Tedde A, Cellini E, Forleo P, Orlacchio A, Guarnieri BM, Petruzzi C, D’Andrea F, Serio A, Sorbi S. Alpha2-macroglobulin polymorphism in Italian sporadic and familial Alzheimer’s disease. Neurosci Lett 2001; 16: 9-12.
18. Pluta R, Kocki J, Maciejewski R, Ułamek-Kozioł M, Jabłoński M, Bogucka-Kocka A, Czuczwar SJ. Ischemia signalling to Alzheimer-related genes. Folia Neuropathol 2012; 50: 322-329.
19. Šerý O, Povová J, Mišek I, Pešák L, Janout V. Molecular mechanisms of neuropathological changes in Alzheimer’s disease: a review. Folia Neuropathol 2013; 51: 1-9.
20. Shi J, Ma C, Lao H, Feng R, Guo Y, Mu N, Li Q, Tan Y, Wang D. No evidence for association between the alpha 2-macroglobulin polymorphism and Alzheimer’s disease in the Han Chinese. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2001; 18: 299-302.
21. Styczynska M, Religa D, Pfeffer A, Luczywek E, Wasiak B, Styczynski G, Peplonska B, Gabryelewicz T, Golebiowski M, Kobrys M, Barcikowska M. Simultaneous analysis of five factors in Polish patients with Alzheimer’s disease. Neurosci Lett 2003; 344: 99-102.
22. Wang X, Luedecking EK, Minster RL, Ganguli M, DeKosky ST, Kamboh MI. Lack of association between alpha2-macroglobulin polymorphisms and Alzheimer’s disease. Hum Genet 2001; 108: 105-108.
23. Zappia M, Cittadella R, Manna I, Nicoletti G, Andreoli V, Bonavita S, Gambardella A, Quattrone A. Genetic association of alpha2- macroglobulin polymorphisms with AD in southern Italy. Neurology 2002; 59: 756-758.
Copyright: © 2014 Mossakowski Medical Research Centre Polish Academy of Sciences and the Polish Association of Neuropathologists. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe